Spotlight on Gynecology/Obstetrics

Credits: 0.25 CME / MOC
Immunotherapy in Cervical Cancer: What’s New?
Krishnansu S. Tewari, MD, FACOG, FACS, FRSM
RMEI Medical Education, LLC

Immunotherapy in Cervical Cancer: What’s New?

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC point(s)
Released: November 29, 2021
Expires: November 28, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for oncology, pathology, gynecologic oncology, and OB/GYN clinicians (MD/DO/NP/PA) who treat patients with cervical cancer.

Learning Objective

Upon completion of this activity, participants should be better able to:

  • Integrate current clinical trial data on immune checkpoint inhibitors into treatment plans for patients with cervical cancer.

Activity Description

Nationally recognized experts Dr. Krishnansu S. Tewari and Dr. Bradley J. Monk present the latest clinical trial data and offer privileged insights on the integration of immunotherapy into the treatment armamentarium for advanced cervical cancer.

Faculty

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM
Professor and Division Director
Division of Gynecologic Oncology
University of California
Irvine, CA

Bradley J. Monk, MD, FACS, FACOG
Professor, Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine at St. Joseph’s Hospital
Medical Director, US Oncology Research Network − Gynecologic Program
Vice President and Member Board of Directors, GOG-Foundation
Co-director, GOG-Partners
Phoenix, AZ

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Bradley J. Monk, MD, FACS, FACOG, has financial relationships with Agenus, Akeso Bio, Aravive, AstraZeneca, Clovis, Eisai, Elevar, EMD Merck, Genmab/Seagen, GOG Foundation, Gradalis, ImmunoGen, Karyopharm, Iovance, Merck, Mersana, Myriad, Novocure, Pfizer, Puma, Regeneron, Roche/Genentech, Sorrento, TESARO/GSK, US Oncology Research, VBL (Consultant); AstraZeneca, Clovis, Eisai, Merck, Roche/Genentech, Tesaro/GSK (Speaker/Speaker’s Bureau).

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM, has financial relationships with Merck (Consultant); Regeneron (Grant/Research Support to UC Irvine for EMPOWER-cervical cancer trial); Merck (Grant/Research Support to UC Irvine for KEYNOTE-826 trial).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 66% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected]

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 66% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme and Merck Sharp & Dohme Corp.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC point(s)
Released: November 29, 2021
Expires: November 28, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for oncology, pathology, gynecologic oncology, and OB/GYN clinicians (MD/DO/NP/PA) who treat patients with cervical cancer.

Learning Objective

Upon completion of this activity, participants should be better able to:

  • Integrate current clinical trial data on immune checkpoint inhibitors into treatment plans for patients with cervical cancer.

Activity Description

Nationally recognized experts Dr. Krishnansu S. Tewari and Dr. Bradley J. Monk present the latest clinical trial data and offer privileged insights on the integration of immunotherapy into the treatment armamentarium for advanced cervical cancer.

Faculty

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM
Professor and Division Director
Division of Gynecologic Oncology
University of California
Irvine, CA

Bradley J. Monk, MD, FACS, FACOG
Professor, Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine at St. Joseph’s Hospital
Medical Director, US Oncology Research Network − Gynecologic Program
Vice President and Member Board of Directors, GOG-Foundation
Co-director, GOG-Partners
Phoenix, AZ

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Bradley J. Monk, MD, FACS, FACOG, has financial relationships with Agenus, Akeso Bio, Aravive, AstraZeneca, Clovis, Eisai, Elevar, EMD Merck, Genmab/Seagen, GOG Foundation, Gradalis, ImmunoGen, Karyopharm, Iovance, Merck, Mersana, Myriad, Novocure, Pfizer, Puma, Regeneron, Roche/Genentech, Sorrento, TESARO/GSK, US Oncology Research, VBL (Consultant); AstraZeneca, Clovis, Eisai, Merck, Roche/Genentech, Tesaro/GSK (Speaker/Speaker’s Bureau).

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM, has financial relationships with Merck (Consultant); Regeneron (Grant/Research Support to UC Irvine for EMPOWER-cervical cancer trial); Merck (Grant/Research Support to UC Irvine for KEYNOTE-826 trial).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 66% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected]

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 66% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme and Merck Sharp & Dohme Corp.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Gynecology/Obstetrics Presentations

0.25 CME / MOC
Vindico Medical Education
Vasomotor Symptoms in Menopause: Prevalence, Burden, and Impact on Quality of Life

Vasomotor Symptoms in Menopause: Prevalence, Burden, and Impact on Quality of Life

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is gynecologists, obstetricians, family medicine physicians, internists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with menopause-related vasomotor symptoms.

Learning Objective

Upon successful completion of this activity, participants should be better able to assess the prevalence, burden, and impact of vasomotor symptoms during menopause on patient quality of life.

Faculty

Risa Kagan, MD, FACOG, CCD, NCMP
Clinical Professor
Department of Obstetrics, Gynecology and Reproductive Sciences
University of California San Francisco
Sutter East Bay Medical Group
Affiliated with Sutter East Bay Medical Foundation
Berkeley, CA

Disclosure:
Consultant: Astellas, Pharmavite, TherapeuticsMD
Speaker Contracted by Ineligible Company: TherapeuticsMD

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Astellas.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at [email protected]

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is gynecologists, obstetricians, family medicine physicians, internists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with menopause-related vasomotor symptoms.

Learning Objective

Upon successful completion of this activity, participants should be better able to assess the prevalence, burden, and impact of vasomotor symptoms during menopause on patient quality of life.

Faculty

Risa Kagan, MD, FACOG, CCD, NCMP
Clinical Professor
Department of Obstetrics, Gynecology and Reproductive Sciences
University of California San Francisco
Sutter East Bay Medical Group
Affiliated with Sutter East Bay Medical Foundation
Berkeley, CA

Disclosure:
Consultant: Astellas, Pharmavite, TherapeuticsMD
Speaker Contracted by Ineligible Company: TherapeuticsMD

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Astellas.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at [email protected]

0.25 CME / MOC
Vindico Medical Education
Treating Vasomotor Symptoms in Menopause: Current and Emerging Therapies

Treating Vasomotor Symptoms in Menopause: Current and Emerging Therapies

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is gynecologists, obstetricians, family medicine physicians, internists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with menopause-related vasomotor symptoms.

Learning Objective

Upon successful completion of this activity, participants should be better able to review the mechanisms of action and clinical evidence regarding the safety and efficacy of emerging treatment options for vasomotor symptoms in menopause, including the benefits and limitations of current therapies.

Faculty

Nanette Santoro, MD
Professor and E. Stewart Taylor Chair of Obstetrics and Gynecology
University of Colorado School of Medicine
Aurora, CO

Disclosure:
Advisor: Astellas

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Astellas.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at [email protected]

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is gynecologists, obstetricians, family medicine physicians, internists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with menopause-related vasomotor symptoms.

Learning Objective

Upon successful completion of this activity, participants should be better able to review the mechanisms of action and clinical evidence regarding the safety and efficacy of emerging treatment options for vasomotor symptoms in menopause, including the benefits and limitations of current therapies.

Faculty

Nanette Santoro, MD
Professor and E. Stewart Taylor Chair of Obstetrics and Gynecology
University of Colorado School of Medicine
Aurora, CO

Disclosure:
Advisor: Astellas

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Astellas.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at [email protected]

0.25 CME / MOC
RMEI Medical Education, LLC
Immunotherapy in Cervical Cancer: What’s New?

Immunotherapy in Cervical Cancer: What’s New?

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC point(s)
Released: November 29, 2021
Expires: November 28, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for oncology, pathology, gynecologic oncology, and OB/GYN clinicians (MD/DO/NP/PA) who treat patients with cervical cancer.

Learning Objective

Upon completion of this activity, participants should be better able to:

  • Integrate current clinical trial data on immune checkpoint inhibitors into treatment plans for patients with cervical cancer.

Activity Description

Nationally recognized experts Dr. Krishnansu S. Tewari and Dr. Bradley J. Monk present the latest clinical trial data and offer privileged insights on the integration of immunotherapy into the treatment armamentarium for advanced cervical cancer.

Faculty

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM
Professor and Division Director
Division of Gynecologic Oncology
University of California
Irvine, CA

Bradley J. Monk, MD, FACS, FACOG
Professor, Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine at St. Joseph’s Hospital
Medical Director, US Oncology Research Network − Gynecologic Program
Vice President and Member Board of Directors, GOG-Foundation
Co-director, GOG-Partners
Phoenix, AZ

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Bradley J. Monk, MD, FACS, FACOG, has financial relationships with Agenus, Akeso Bio, Aravive, AstraZeneca, Clovis, Eisai, Elevar, EMD Merck, Genmab/Seagen, GOG Foundation, Gradalis, ImmunoGen, Karyopharm, Iovance, Merck, Mersana, Myriad, Novocure, Pfizer, Puma, Regeneron, Roche/Genentech, Sorrento, TESARO/GSK, US Oncology Research, VBL (Consultant); AstraZeneca, Clovis, Eisai, Merck, Roche/Genentech, Tesaro/GSK (Speaker/Speaker’s Bureau).

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM, has financial relationships with Merck (Consultant); Regeneron (Grant/Research Support to UC Irvine for EMPOWER-cervical cancer trial); Merck (Grant/Research Support to UC Irvine for KEYNOTE-826 trial).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 66% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected]

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 66% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme and Merck Sharp & Dohme Corp.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC point(s)
Released: November 29, 2021
Expires: November 28, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for oncology, pathology, gynecologic oncology, and OB/GYN clinicians (MD/DO/NP/PA) who treat patients with cervical cancer.

Learning Objective

Upon completion of this activity, participants should be better able to:

  • Integrate current clinical trial data on immune checkpoint inhibitors into treatment plans for patients with cervical cancer.

Activity Description

Nationally recognized experts Dr. Krishnansu S. Tewari and Dr. Bradley J. Monk present the latest clinical trial data and offer privileged insights on the integration of immunotherapy into the treatment armamentarium for advanced cervical cancer.

Faculty

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM
Professor and Division Director
Division of Gynecologic Oncology
University of California
Irvine, CA

Bradley J. Monk, MD, FACS, FACOG
Professor, Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine at St. Joseph’s Hospital
Medical Director, US Oncology Research Network − Gynecologic Program
Vice President and Member Board of Directors, GOG-Foundation
Co-director, GOG-Partners
Phoenix, AZ

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Bradley J. Monk, MD, FACS, FACOG, has financial relationships with Agenus, Akeso Bio, Aravive, AstraZeneca, Clovis, Eisai, Elevar, EMD Merck, Genmab/Seagen, GOG Foundation, Gradalis, ImmunoGen, Karyopharm, Iovance, Merck, Mersana, Myriad, Novocure, Pfizer, Puma, Regeneron, Roche/Genentech, Sorrento, TESARO/GSK, US Oncology Research, VBL (Consultant); AstraZeneca, Clovis, Eisai, Merck, Roche/Genentech, Tesaro/GSK (Speaker/Speaker’s Bureau).

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM, has financial relationships with Merck (Consultant); Regeneron (Grant/Research Support to UC Irvine for EMPOWER-cervical cancer trial); Merck (Grant/Research Support to UC Irvine for KEYNOTE-826 trial).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 66% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected]

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 66% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme and Merck Sharp & Dohme Corp.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.50 CME
Postgraduate Institute for Medicine
On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer

On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: October 7, 2021
Expires: October 7, 2022
30 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, gynecologic oncologists, surgical oncologists, obstetricians and gynecologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with ovarian cancer.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Select genetic testing for patients with newly diagnosed advanced ovarian cancer
  • Utilize clinical features and genetic information to plan treatment for patients with newly diagnosed advanced ovarian cancer
  • Compare and contrast current and emerging treatment strategies for patients with newly diagnosed ovarian cancer
  • Manage adverse events associated with maintenance therapy for patients with newly diagnosed advanced ovarian cancer

Activity Description

On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer aims to focus on critical care decisions for patients with newly diagnosed advanced ovarian cancer. This activity will also provide a unique take by including the patient voice as part of the discussion. You’ll hear directly from a patient living with ovarian cancer who will share her experience along with important information she feels physicians should know when caring for these patients.

Statement of Educational Need

Ovarian neoplasms, consisting mostly of epithelial ovarian cancer (~90%), is the leading cause of death from gynecologic cancer in the United States. Improved outcomes from multiple phase 3 studies have shifted the treatment paradigm for patients with newly diagnosed advanced ovarian cancer. This progress brings new challenges, which force HCPs to make critical decisions that require extensive knowledge and careful thought. This program will help clinicians make those critical decisions leading to improved care for patients with this challenging disease.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Robert Coleman, MD, FACS, FACOG
Chief Scientific Officer
Texas Oncology - US Oncology Research
Houston, Texas

Consultant/Advisory Board: Deciphera, Agenus, Gradalis, Alkermes, Epsilogen, Karyopharm, Merck, GSK, Seagen, Slovis, Novocure, DNAMx, AstraZeneca, Genelux, Genentech/Roche, Abbvie, OncXerna
Research Funding: Merck, Abbvie, AstraZeneca, Seagen, Genentech/Roche

Faculty

Angeles Alvarez Secord, MD
Professor of Obstetrics and Gynecology
Duke Cancer Institute
Durham, North Carolina

Consulting Fees/Advisory Board: Myriad, AbbVie, Aravive, AstraZeneca, Eisai, Tesaro/GSK, Regeneron
Research Funding: AbbVie, AstraZeneca, Boehringer Ingelheim, Clovis, Eisai, Immutep Ltd, Merck, Oncoquest, PharmaMar, Roche/Genentech, Seagen Inc., Tesaro/GSK, VBL Therapeutics, National Cancer Trial Network


Paula Anastasia, RN, MN, AOCN
GYN-Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, California

Consulting Fees: Merck Advisory Board
Speakers’ Bureau (non-branded): Genentech


Patient Advocate and Ovarian Cancer Survivor
Kathy Jennings


No relevant financial relationships to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca and Merck.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

[email protected]

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: October 7, 2021
Expires: October 7, 2022
30 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, gynecologic oncologists, surgical oncologists, obstetricians and gynecologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with ovarian cancer.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Select genetic testing for patients with newly diagnosed advanced ovarian cancer
  • Utilize clinical features and genetic information to plan treatment for patients with newly diagnosed advanced ovarian cancer
  • Compare and contrast current and emerging treatment strategies for patients with newly diagnosed ovarian cancer
  • Manage adverse events associated with maintenance therapy for patients with newly diagnosed advanced ovarian cancer

Activity Description

On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer aims to focus on critical care decisions for patients with newly diagnosed advanced ovarian cancer. This activity will also provide a unique take by including the patient voice as part of the discussion. You’ll hear directly from a patient living with ovarian cancer who will share her experience along with important information she feels physicians should know when caring for these patients.

Statement of Educational Need

Ovarian neoplasms, consisting mostly of epithelial ovarian cancer (~90%), is the leading cause of death from gynecologic cancer in the United States. Improved outcomes from multiple phase 3 studies have shifted the treatment paradigm for patients with newly diagnosed advanced ovarian cancer. This progress brings new challenges, which force HCPs to make critical decisions that require extensive knowledge and careful thought. This program will help clinicians make those critical decisions leading to improved care for patients with this challenging disease.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Robert Coleman, MD, FACS, FACOG
Chief Scientific Officer
Texas Oncology - US Oncology Research
Houston, Texas

Consultant/Advisory Board: Deciphera, Agenus, Gradalis, Alkermes, Epsilogen, Karyopharm, Merck, GSK, Seagen, Slovis, Novocure, DNAMx, AstraZeneca, Genelux, Genentech/Roche, Abbvie, OncXerna
Research Funding: Merck, Abbvie, AstraZeneca, Seagen, Genentech/Roche

Faculty

Angeles Alvarez Secord, MD
Professor of Obstetrics and Gynecology
Duke Cancer Institute
Durham, North Carolina

Consulting Fees/Advisory Board: Myriad, AbbVie, Aravive, AstraZeneca, Eisai, Tesaro/GSK, Regeneron
Research Funding: AbbVie, AstraZeneca, Boehringer Ingelheim, Clovis, Eisai, Immutep Ltd, Merck, Oncoquest, PharmaMar, Roche/Genentech, Seagen Inc., Tesaro/GSK, VBL Therapeutics, National Cancer Trial Network


Paula Anastasia, RN, MN, AOCN
GYN-Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, California

Consulting Fees: Merck Advisory Board
Speakers’ Bureau (non-branded): Genentech


Patient Advocate and Ovarian Cancer Survivor
Kathy Jennings


No relevant financial relationships to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca and Merck.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

[email protected]